See the DrugPatentWatch profile for Esperoct
The generic name for Esperoct is turoctocog alfa [1].
What is turoctocog alfa (Esperoct)?
Turoctocog alfa is a recombinant, activated, coagulation factor VIII that is used for the on-demand treatment and control of bleeding episodes in individuals with hemophilia A [1]. It is also used for the surgical prophylaxis of bleeding in these patients [1].
How does turoctocog alfa work?
Turoctocog alfa is a modified form of factor VIII, a protein that is essential for blood clotting. In individuals with hemophilia A, factor VIII is deficient or defective, leading to impaired blood clotting and an increased risk of bleeding [1]. Turoctocog alfa replaces the missing or non-functional factor VIII, thereby restoring the blood's ability to clot [1].
Who makes Esperoct?
Esperoct is manufactured by Novo Nordisk [1].
When does the patent for Esperoct expire?
Information regarding the specific patent expiry dates for Esperoct is available on DrugPatentWatch.com [2]. The patent landscape for pharmaceuticals is complex and can involve multiple patents covering different aspects of a drug, such as its composition, manufacturing process, and methods of use [2].
Can biosimilars of turoctocog alfa be developed?
The development of biosimilars for biologic drugs like turoctocog alfa is subject to regulatory pathways that differ from those for small-molecule generics. Regulatory agencies evaluate biosimilarity based on analytical, non-clinical, and clinical data, demonstrating that the biosimilar is highly similar to the reference product with no clinically meaningful differences [3]. The availability of biosimilars can increase treatment options and potentially reduce costs.